Arena Pharmaceuticals Inc
featured
Check out which companies are making headlines after the bell Thursday:
» Read More
More
-
Stocks rallied Wednesday as the dollar pulled back and Fed Chairman Ben Bernanke pledged to keep rates low for a long time. Financials were among the top gainers.
-
Stocks rallied Wednesday as the dollar pulled back and Fed Chairman Ben Bernanke pledged to keep rates low for a long time. Financials were among the top gainers.
-
Stocks opened slightly higher Wednesday as the market looked for direction ahead of Fed Chairman Ben Bernanke's semi-annual report on monetary policy and the economy.
-
The Financial Industry Regulatory Authority, the stock markets' self-policing arm, is looking into trading in Vivus shares around the time it announced its positive late-stage test results on its diet drug, Qnexa.
-
Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.
-
I can’t wait until this drug rises to the level where it gets on Joe Kernen’s radar screen because, boy, is he gonna have a good time (not just with the drug perhaps, but mostly with talking on TV about it.) A little TMI, I know, but that’s Joe.
-
I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.
-
Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.
-
Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.
-
Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.
-
There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.
-
Stocks resumed their ascent Friday, after snapping the week's winning streak on Thursday, as investors braced for a volatile day due to quadruple witching.
-
Stock index futures pointed to a slightly higher open for Wall Street, with no significant economic news but quadruple-witching on the table.
-
Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.
-
Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.
-
This company’s diabetes and obesity drug could generate huge returns for investors.
-
For years now, but especially in recent months, I've been covering the obesity epidemic. I regularly report on the statistics and the experimental drug data, detached and "objective" as I think any good reporter should be. It just didn't occur to me that the target population might include my sister.
-
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
-
There is no quid pro quo in my line of work. At least there shouldn't be. But when you do two stories on CNBC and another one on "TODAY" that mentions a company's drug and profiles a patient who appears to have been a "responder" in one of its clinical trials you expect a certain basic professional level of cooperation and assistance.
-
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.